  - $9.34
-0.03 (-0.32%) - 02/22/19
- KEYB
02/22/19
DOWNGRADEKEYB
Sector Weight Allscripts downgraded to Sector Weight from Overweight at KeyBanc - 02/22/19
- SBSH
02/22/19
DOWNGRADETarget $12
SBSH
Neutral Allscripts downgraded to Neutral from Buy at Citi Citi analyst Stephanie Demko downgraded Allscripts to Neutral and lowered her price target for the shares to $12 from $14. The "implied steepness" in the ramp to long-term guidance "may prove out of reach," while near-term challenges in investor sentiment could keep shares range bound, Demko tells investors in a post-earnings research note. She points out the stock traded down 11% as a miss on headline numbers and fiscal 2019 guidance "likely struck a raw nerve with investors" following management's bullish tone in January. - 01/18/19
- KEYB
01/18/19
UPGRADETarget $15
KEYB
Overweight Allscripts upgraded to Overweight from Sector Weight at KeyBanc As previously reported, KeyBanc analyst Donald Hooker upgraded Allscripts to Overweight with a $15 price target following the company's divestiture of Netsmart. In a research note to investors, Hooker says he sees material upside in the company's share price if Allscripts can show any acceleration of growth in 2019 or 2020. - 01/18/19
- KEYB
01/18/19
UPGRADETarget $15
KEYB
Overweight Allscripts upgraded to Overweight from Sector Weight at KeyBanc KeyBanc analyst Donald Hooker upgraded Allscripts to Overweight with a $15 price target. - $3.66
0.06 (1.67%) - 10/18/18
- WBLR
10/18/18
NO CHANGEWBLR
Outperform William Blair sees catalysts for Castlight shares after two-month selloff William Blair analyst Jeffrey Garro points out that shares of Castlight Health (CSLT) have sold off steadily over the last two months following the announcement of Walmart's (WMT) nonrenewal in conjunction with weaker than expected bookings in the second quarter. The analyst, however, believes there is still support around the size of the market opportunity and the value generated by the company's healthcare navigation and well-being guidance platform for employers. Nonetheless, it will take better near-term execution before the company can reorient investors toward higher growth expectations and close the gap between its valuation and the peer group, Garro tells investors in a research note. He believes, though, that Castlight Health "may receive a pass" on the Walmart loss in time as more details emerge. Further, the looming general availability of Castlight Complete and achieving adjusted EBITDA profitability for the first time in Q4 can serve as near-term catalysts, Garro contends. He keeps an Outperform rating on the shares. - 08/16/18
- CANT
08/16/18
NO CHANGECANT
Overweight Cantor Fitzgerald backs 'positive' view of healthcare IT segment Cantor Fitzgerald Steven Halper tells investors in a research note that he is maintaining a positive investment view of the healthcare IT segment, and believes demand for products and services in the sector will continue to drive long-term growth. Specifically, he continues to rate Cerner (CERN) and Evolent Health (EVH) Overweight, as both are "nicely" leveraged to population health, with Evolent mostly a pure play in the segment. Within managed care, Halper believes Overweight-rated UnitedHealth (UNH) remains well-positioned with its Optum segment. - 07/31/18
- CANT
Castlight Health loss of Walmart overshadows Q2 beat, says Cantor Castlight Health's (CSLT) beat in Q2 was overshadowed by the loss of large client Walmart (WMT) and the initiation of a cost-restructuring program to mitigate the loss of revenue in 2019, Cantor Fitzgerald analyst Steven Halper tells investors in a research note. Despite positive discussions recently, Walmart decided not to renew and migrate to Complete, the analyst adds. With 25% upside potential to his $5 price target, the analyst maintains an Overweight rating on Castlight amid the post-earnings selloff. - 07/31/18
- CHDN
07/31/18
DOWNGRADECHDN
Neutral Castlight Health downgraded to Neutral from Buy at Chardan - $62.43
0.02 (0.03%) - 04/10/19
- RHCO
Cerner upgraded to Buy from Hold at SunTrust - 04/10/19
- RHCO
04/10/19
UPGRADETarget $76
RHCO
Buy Cerner upgraded to Buy from Hold at SunTrust SunTrust analyst Sandy Draper upgraded Cerner to Buy and raised his price target to $76 from $60, saying the company's "margin pickup", expanded buyback, and cash flows will "yield positive results" for the stock. While the analyst expects a tough electronic health record end market to continue, he adds that the presence of an activist investor and the appointment of four new board members will give Cerner valuation a floor. - 04/10/19
- ADAM
04/10/19
NO CHANGETarget $68
ADAM
Buy Cerner board refreshment, other announcements encouraging, says Canaccord Canaccord analyst Richard Close maintained a Buy rating and $68 price target on Cerner after the company announced plans to "refresh" its board, committed to improving margins and operations and increase share repurchases as part of a cooperation agreement with Starboard. In a research note to investors, Close says he is "encouraged" by the moves after previously commending the company in initiating a dividend, as the moves further solidify that management is focused on driving shareholder returns while delivering on commitments to existing and potential client partners. - 04/10/19
- SBSH
04/10/19
NO CHANGETarget $77
SBSH
Buy Cerner price target raised to $77 from $68 at Citi Citi analyst Stephanie Demko raised her price target for Cerner to $77 from $68 and reiterates a Buy rating on the shares following the company's cooperation agreement with activist Starboard Value. The analyst believes Cerner is a "core HCIT asset with strong potential" in both margin expansion and capital returns. - $29.07
0.05 (0.17%) - 02/21/19
- RHCO
02/21/19
NO CHANGETarget $35
RHCO
Hold Computer Programs price target raised to $35 from $30 at SunTrust SunTrust analyst Sandy Draper raised his price target on Computer Programs to $35 after its Q4 earnings beat that he says was driven by lower costs. The analyst expects the company's "aggressive cost cuts to more than offset decreasing contributions from MU3" but also keeps his Hold rating considering the limited upside potential for the stock relative to his target. - 02/15/19
- PIPR
02/15/19
NO CHANGETarget $35
PIPR
Neutral Piper encouraged by Computer Programs bookings, still cautious on visibility Following Computer Programs' reports of mixed Q4 results, Piper Jaffray analyst Sean Wieland said he encouraged to see strength in bookings and believes the fact that recurring revenue is growing as a portion of the business adds visibility. However, he remains cautious about the high variability and uncertainty in the company's model, noting that Computer Programs doesn't provide revenue and profitability guidance. He raised his price target on shares to $35 from $29, largely to account for a lower tax rate, but keeps a Neutral rating on the stock. - 12/03/18
- CANT
Cantor 'not too worried' about Amazon's healthcare IT initiative Cantor Fitzgerald analyst Steven Halper is "not too worried" after Amazon (AMZN) last week confirmed plans to sell software that will mine patient medical records to reduce medical expenses. The analyst does not expect traditional electronic medical record vendors, including Allscripts (MDRX), Cerner (CERN), Computer Program and Systems (CPSI) and NextGen (NXGN) to be impacted by Amazon. It "remains to be seen whether Amazon's forays into the healthcare industry will be truly disruptive," says the analyst. He believes Amazon is likely positioning itself to benefit from pharmaceutical and medical supply sales. - 08/03/18
- PIPR
08/03/18
NO CHANGETarget $29
PIPR
Neutral Computer Programs price target lowered to $29 from $32 at Piper Jaffray Piper Jaffray analyst Sean Wieland lowered his price target on Computer Programs to $29 after its Q2 earnings miss, saying the wide margin was attributed mainly to client delays in purchasing Meaningful Use required systems. The analyst notes that the management is confident in the second half recovery given the queue of pending implementations, but still sees risks of "very high stimulus incentive eligibility requirements, less than anticipated EHR adoption despite stimulus incentives, and competition". Wieland keeps his Neutral rating on Computer Programs. - $5.39
(0.00%) - 02/28/19
- DADA
Fitbit upgraded to Buy from Neutral at DA Davidson - 02/28/19
- DADA
02/28/19
UPGRADETarget $7
DADA
Buy Fitbit upgraded to Buy from Neutral at DA Davidson DA Davidson analyst Tom Forte upgraded Fitbit to Buy and raised his price target to $7 from $5.50 after its Q4 results and outlook for Q1 and FY19. The analyst attributes the upgrade to his view of "improvements that the management has made to the company's operating results, including a return to both unit and sales growth." Forte is also positive on Fitbit's "attractive balance sheet" and the progress made in its healthcare services efforts, saying the risk/reward on the stock is favorable given the after-market decline in the share price. - 02/28/19
Fly Intel: Top five analyst upgrades Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Fitbit (FIT) upgraded to Buy from Neutral at DA Davidson analyst Tom Forte citing Q4 results and outlook for Q1 and FY19. 2. Hain Celestial (HAIN) upgraded to Overweight from Neutral at JPMorgan with analyst Ken Goldman citing the company's "compelling" investor day, the analyst has increased confidence in Hain's ability to drive margin growth over the next few years. 3. Athene Holding (ATH) upgraded to Outperform from Market Perform at BMO Capital with analyst James Fotheringham saying the valuation multiple on the stock may have finally passed its trough at its current 5.5-times two-year forward earnings multiple and believes that its core business should be valued at 6.4-times. 4. Wabco (WBC) upgraded to Neutral from Underweight at JPMorgan and to Hold from Sell at Vertical Research. 5. Globus Medical (GMED) upgraded to Buy from Neutral at UBS with analyst Matthew Taylor saying the company has delivered several quarters in a row of improving spine growth, which confirms robot placements are leading to implant pull-through. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. - 04/05/19
- DADA
04/05/19
NO CHANGETarget $7
DADA
Buy Fitbit's Snap partnership a positive, says DA Davidson DA Davidson analyst Tom Forte kept his Buy rating and $7 price target on Fitbit (FIT) after it announced a Bitmoji partnership with Snap (SNAP) that allows users to access Bitmoji avatars on the face of their Fitbit smartwatches. The analyst says the deal is a positive for Fitbit as it seeks to increase customer engagement and "make personal health more fun". - $16.83
0.07 (0.42%) - 11/01/18
- MSCO
11/01/18
UPGRADEMSCO
Equal Weight NextGen Healthcare upgraded to Equal Weight from Underweight at Morgan Stanley - 11/01/18
11/01/18
UPGRADETarget $16
Equal Weight After consensus comes in, Morgan Stanley ups NextGen Healthcare to Equal Weight As previously reported, Morgan Stanley analyst Ricky Goldwasser upgraded NextGen Healthcare to Equal Weight from Underweight, noting that revisions to consensus estimates following the company's quarterly report has made the Street view more aligned with his own view of how growth will be paced. While strong bookings provide improved mid-term visibility, the pace of growth is likely to be more measured than management projects, believes Goldwasser. He raised his price target on NextGen Healthcare shares to $16 from $12. - 01/11/19
- DOTC
NextGen Healthcare upgraded to Buy from Neutral at Dougherty |